2016-11-10T12:05:12-00:00 2015-12-31 KPMG LLP 1918 8th Avenue Suite 2900 Seattle WA 98101 990 2015-01-01 910653422 Benaroya Research Institute at Virginia Mason BENA 2063426500 1201 Ninth Avenue Seattle WA 981012795 Homer W Lane Jr Executive DirectorCFO 2016-11-09 true Sue Robison 2069134000 2015 2017-02-10 21:41:12Z Gerald Nepom MD PhD 1201 Ninth Avenue Seattle WA 98101 67161738 false X http://www.benaroyaresearch.org X 1956 WA To conduct and encourage high quality medical, surgical, and scientific research and research training in disease and problems of medical importance. 22 17 326 9 0 54174085 59709893 6639555 7021290 164405 -107705 350163 347680 61328208 66971158 17599162 23704570 0 25135170 25752883 0 0 19170074 18024768 61904406 67482221 -576198 -511063 85390333 85438161 43346845 45136173 42043488 40301988 X See Schedule O false false 27986467 20372963 Immune Tolerance Network Program. See Schedule O. 9094684 2356655 Translational Program. See Schedule O. 6554218 363343 Diabetes Program. See Schedule O. 13367403 611609 7021290 57002772 true true false true false false false false false true true true false false false false true false false false true true false false false false false true false true true false false true false false false false false false false true false false false false true false false false false true 102 0 true 326 true false false false false false false false false false false X 22 17 false false false false true true true true true false false true true true true true true true true false WA X Homer W Lane Jr Executive DirectorC 2063426508 1201 Ninth Avenue Seattle WA 981012795 Carla Greenbaum MD Director 040.00 X 212388 0 30886 Gerald Nepom MD PhD Ex Officio, Director 040.00 X X 479083 0 44592 Joyce Lammert MD PhD Director 001.00 050.00 X 0 575689 92758 John Corman MD Director 001.00 050.00 X 0 524046 39354 Gary Kaplan MD Director 001.00 054.00 X 0 1463343 1123646 Tom Cohen Director 001.00 X 0 0 0 Rebecca Campbell Director 001.00 X 0 0 0 Kristi Pangrazio Director, Chairman 001.00 004.00 X X 0 0 0 Margaret Morrow Director, Secretary 001.00 X X 0 0 0 Frank Dvorak PhD Director 001.00 X 0 0 0 Trish Markey Director 001.00 X 0 0 0 Edward Drosdick Director 001.00 X 0 0 0 David Williams Director, Treasurer 001.00 X X 0 0 0 Ditman Johnson Director 001.00 X 0 0 0 Michael Gallatin Director 001.00 X 0 0 0 Jessica Muffett Director 001.00 X 0 0 0 Carla DewBerry Director, Vice-Chair 001.00 X X 0 0 0 Ann Sobil Director 001.00 X 0 0 0 Christopher Wilson MD Director 001.00 X 0 0 0 Nabil Istafanous Director 001.00 X 0 0 0 Ben Reiber Director 001.00 X 0 0 0 Catherine Zimmerman Director 001.00 X 0 0 0 Homer Lane Jr Executive Director, Chief Financial Officer 040.00 X 307405 0 32594 Jane Buckner MD Research Member 040.00 X 259514 0 26892 William Kwok PhD Research Member 040.00 X 216831 0 26892 Lynn Rose Director Scientific Administration 040.00 X 182021 0 23520 Steven Ziegler PhD Research Member 040.00 X 189110 0 18496 James Lord MD Research Member 040.00 X 202127 0 21438 2048479 2563078 1481068 35 false true false Insight Globall LLC PO Box 198226 Atlanta GA 30384 Consulting 198540 KPMG LLP 1918 Eighth Ave Suite 2900 Seattle WA 98101 Auditing Consulting 105381 2 3500000 46581827 9628066 85000 59709893 Commercial Studies 621500 4028943 4028943 Collaborative research core services 621500 2992347 2992347 7021290 -107705 -107705 538260 190580 347680 347680 347680 66971158 7021290 239975 21239142 21239142 0 2465428 2465428 0 2039840 1265487 774353 0 17213070 12770397 4442673 1436495 1015651 420844 3740387 2644581 1095806 1323091 935471 387620 0 7322 7322 91100 91100 0 0 2592679 2046908 545771 197419 7000 190419 152153 58480 93673 1116074 271542 844532 0 2760019 2395025 364994 350180 315161 35019 0 144822 125156 19666 812900 707223 105677 0 3505374 2854002 651372 44744 44744 Supplies 3597857 3528154 69703 Other Purchased Services 311275 191582 119693 Patient Costs 1216493 1216493 Research Participants Fee 404728 404728 719629 545161 174468 67482221 57002772 10479449 0 9549793 9334155 747735 6095 11311167 11688324 314740 854913 505401 454115 70056830 39101568 32304086 30955262 8505508 9139241 21252233 22130376 899670 875680 85390333 85438161 10220796 12044459 4074559 4410224 9755000 9425000 19296490 19256490 43346845 45136173 X 24026666 20378881 8864453 8690843 9152369 11232264 42043488 40301988 85390333 85438161 -511063 -1230437 X false true X true true true X Virginia Mason Medical Center Seattle WA 34328409 38329362 44973133 54174085 59709893 231514882 34328409 38329362 44973133 54174085 59709893 231514882 25966127 205548755 1724806 560734 642011 707157 430555 4065263 2391006 4701834 6122655 6639555 7021290 26876340 262456485 0.78320 0.74980 X 0.00000 0.00000 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED X 108173 46593 154766 67482221 1112971638 67482221 1113126404 1000000 1000000 250000 250000 1000000 1000000 1000000 1000000 4000000 6000000 133874 122035 138835 154766 549510 250000 250000 250000 250000 1000000 1500000 127874 114035 119335 108173 469417 false false false false false false false false false false false II-A A Benaroya Research Institute at Virginia Mason, EIN 91-0653422, 1201 Ninth Avenue, Seattle, WA 98101. Non-electing member. 0 Lobbying Expenditures. Excess Lobbying Expenditures 0. II-A A continued Virginia Mason Health System, EIN 91-1351110, 1100 Ninth Avenue, Seattle, WA 98101. Non-electing member. 0 Lobbying Expenditures. Excess Lobbying Expenditures 0 II-A A continued Virginia Mason Institute, EIN 26-3763656, 1100 Ninth Avenue, Seattle, WA 98101. Non-electing member. 0 Lobbying Expenditures, 0 Excess Lobbying Expenditures. II-A A continued Virginia Mason Medical Center, EIN 91-0565539, 1100 Ninth Avenue, Seattle, WA 98101. Electing member. Grassroots Lobbying Expenditures 108,173 Direct Lobbying Expenditures 46,593. Excess Lobbying Expenditures 0. Tax year ending December 31, 1998 was the first year in which Virginia Mason Medical Center made the election under Section 501h. The election was not revoked before the start of the tax year ending December 31, 2015. false false true true 756906 756906 48672224 22940313 25731911 196862 196862 19856562 15964393 3892169 574276 574276 30955262 Financial derivatives and other financial products Closely-held equity interests Interest in Net Assets of Virginia Mason Health System 22130376 F 22130376 Federal income taxes 65740721 -1230437 -1230437 66971158 66971158 67482221 67482221 67482221 true East Asia and the Pacific Conferences Medical Research 5551 Europe Including Iceland and Greenland Conferences Medical Research 43627 North America Conferences Medical Research 1244 South America Conferences Medical Research 1647 52069 52069 Europe Including Iceland and Greenland Medical Research 3843 Wire Transfer Europe Including Iceland and Greenland Medical Research 748064 Wire Transfer Europe Including Iceland and Greenland Medical Research 1058740 Wire Transfer Europe Including Iceland and Greenland Medical Research 162417 Wire Transfer North America Medical Research 243492 Wire Transfer North America Medical Research 37556 Wire Transfer North America Medical Research 9704 Wire Transfer North America Medical Research 176636 Wire Transfer North America Medical Research 24976 Wire Transfer 9 false false false false false false Part I Line 2 Subrecipient Monitoring Policy - medical research sub awards - BRI has formal policies and procedures to assure full compliance with applicable policies and laws governing Federal Grants. The Subrecipient Monitoring policy provides assurance that subrecipients comply with Federal Grant regulations. This policy sets the criteria to establish eligibility of subrecipients to provide annual audited financial reports and the annual OMB single audit report that identify compliance with federal laws and regulations. The reports are analyzed with emphasis on auditors assessment of subrecipient internal controls and a standardized Risk Assessment is presented to management on each subrecipient. A Management Letter is issued to each subrecipient showing any findings on their OMB single audit report, and measurements are set for increased monitoring when an elevated level of risk is established. Management has communicated with an educated administrative staff regarding implementation of this policy. The Director of Grants and Contracts is responsible for monitoring subrecipient adherence to financial regulations. The principal investigator is responsible for overseeing the satisfactory performance of the sub-award to ensure that goals are achieved. If there are unusual or unforeseen items, these will be investigated. Part I Line 3f The expenditures were actual expenses incurred in the region based on individual expense reports and tracking of expenditures by grant or department on the accrual basis of accounting. Part II Line 1 The expenditures were expenses incurred in the region based on award goals on the accrual basis of accounting. true Ann&Robert H Lurie Children's Hospital of Chicago 225 East Chicago Ave No 205 Chicago IL 606112991 362170833 501c3 46651 Medical Research Arizona State University Office for Research and Sponsored P Tempe AZ 852876011 860196696 Arizona 17354 Medical Research Arkansas Children's Hospital Research Institute Financial Services Slot 663 attn Am Little Rock AR 722023591 710694931 501c3 223161 Medical Research Asthma Inc 9725 3rd Ave NE Suite 500 Seattle WA 98115 237219813 501c3 154854 Medical Research Baylor College of Medicine One Baylor Plaza Suite 600-D Houston TX 770303411 741613878 501c3 11434 Medical Research Brigham And Women's Hospital Bank of America NA POBox 3887 Boston MA 022413887 042312909 501c3 92559 Medical Research Case Western Reserve University 2123 Martin Luther King Drive Glenn Cleveland OH 44106 341018992 501c3 24710 Medical Research Cedars-Sinai Medical Center Sponsored Research and Fund Adminst Los Angeles CA 900481804 951643307 501c3 237343 Medical Research Columbia University Trustees of PO Box 29789 General Post Office New York NY 100879789 135598093 501c3 194145 Medical Research Dana-Farber Cancer Institute Inc 450 Brookline Ave 431C Boston MA 02215 042263040 501c3 22932 Medical Research Dermatology Research Assoc Inc 301 Carriage Place Manhatten Beach CA 90266 273947370 74048 Medical Research Duke University Cell Biology Jenkins/Hogan Durham NC 27710 560532129 501c3 389699 Medical Research Emory University 1599 Clifton Road NE 4th floor Atlanta GA 30322 580566256 501c3 432272 Medical Research Feinstein Institute for Medical Research 350 Community Drive Manhasset NY 11030 112673595 501c3 30048 Medical Research Fred Hutchinson Cancer Research Center 1100 Fairview Ave N J6-330 PO Box 1 Seattle WA 981091024 237156071 501c3 91156 Medical Research Hospital for Special Surgery 535 East 70th Street New York NY 10021 131624135 501c3 17233 Medical Research Icahn School of Medicine at Mount Sinai 101 Woodruff Circle - 7126 WMRB Att Atlanta GA 30322 580566256 501c3 389327 Medical Research Indiana University 620 Union Drive Room 618 Indianapolis IN 462025167 356001673 501c3 24462 Medical Research Johns Hopkins University Department of Pediatrics 400 N Wolf Baltimore MD 21287 520595110 501c3 686775 Medical Research Jonathan Corren MD Inc 10780 Santa Monica Blvd 280 Allergy Los Angeles CA 90025 462346264 205667 Medical Research Joslin Diabetes Center One Joslin Place Boston MA 02215 042203836 501c3 6954 Medical Research La Jolla Institute for Allergy & Immunology 9420 Athena Circle La Jolla CA 92037 330328688 501c3 133404 Medical Research Louisiana State University Health Sciences Center 1501 Kings Highway Shreveport LA 711303932 720702002 Louisiana 12477 Medical Research Massachusetts General Hospital Bank of America NA PO Box 414876 Boston MA 02241 041564655 501c3 5123674 Medical Research Mayo Clinic 200 First Street Southwest Rochester MN 55905 416011702 501c3 6862 Medical Research Medical University of South Carolina 19 Hagood Avenue Ste 604 MSC 808 Charleston SC 29425 576000722 South Carolina 19412 Medical Research National Jewish Health 1400 Jackson Street M213 Denver CO 80206 742044647 501c3 58660 Medical Research New York University School of Medicine 1 Park Ave Fl 11 New York NY 10016 135562308 501c3 30637 Medical Research New York University-School of Medicine Bank of America PO Box 415026 Boston MA 022415026 135562308 501c3 44937 Medical Research Newport Beach Clinical Research Associates Inc 3900 West Coast Hwy Suite 330 Newport Beach CA 92663 204957981 13902 Medical Research Northwestern University 750 N Lake Shore Drive Chicago IL 60611 362167817 501c3 257253 Medical Research Norton Neurosciences InstituteCommunity Med Assoc 224 East Broadway 7th floor Louiseville KY 402022025 611276316 501c3 9109 Medical Research Ohio State University Office of Sponsored Programs 1960 K Columbus OH 43210 316025986 501c3 39878 Medical Research Oklahoma Medical Research Foundation 825 NE 13th Street Oklahoma City OK 73104 730580274 501c3 43026 Medical Research Polyclinic Madison Center 904 7th Ave 6th Floo Seattle WA 98104 910369070 27736 Medical Research Rockefeller University 1230 York Ave Financial Post Award New York NY 100656307 131624158 501c3 185983 Medical Research Rogosin Institute 504 East 74th St 5th floor New York NY 100214782 133184198 501c3 20525 Medical Research Rutgers the State University of New Jersey Office of Research and Sponsored Pr New Brunswick NJ 089018559 910961784 501c3 428510 Medical Research Sanford Research 2301 E 60th St N Attn Clinical Rese Sioux Falls SD 57104 460450378 501c3 15618 Medical Research Seattle Childrens Hospital PO Box 24728 Seattle WA 981240728 910564748 501c3 796029 Medical Research South Suburban Neurology 3235 Vollmer Rd 110 Flossmoor IL 60422 363142574 13180 Medical Research St Jude Children's Research Hospital Inc PO Box 1000 Dept 949 Memphis TN 381480949 620646012 501c3 86444 Medical Research Stanford University PO Box 44253 San Francisco CA 941444253 941156365 501c3 1055572 Medical Research Sutter East Bay Hospitals PO Box 742585 Los Angeles CA 900742585 941196176 501c3 12334 Medical Research Tulane University 1430 Tulane Ave Dermatology 8036 At New Orleans LA 70112 720423889 501c3 32326 Medical Research UC Regents University California SanDiego UCSD Central Cashier 9500 Gilman Dr La Jolla CA 920930009 426004813 501c3 532975 Medical Research Univ of Minnesota Regents 450 McNamara Alumni Center Minneapolis MN 554552070 416007513 Minnesota 10423 Medical Research Univ of Texas SW Med Ctr Grants Management PO Box 841753 Dallas TX 752841753 756002868 Texas 8571 Medical Research University of Alabama at Birmingham 1720 2nd Ave South AB 990 Birmingham AL 35294 636005396 Alabama 20726 Medical Research University of California The Regents of Accounting Office CGA Box 0897 San Francisco CA 941430897 946002123 501c3 48350 Medical Research University of California San Francisco Accounting Office - CGA Box 0897 San Francisco CA 941430897 946036493 501c3 5853939 Medical Research University of California Davis The Regents of Cashiers Office PO Box 989062 West Sacramento CA 957989062 946036494 501c3 21973 Medical Research University of Chicago Section Of Endocrinology 5841 S Mar Chicago IL 60637 362177139 501c3 114253 Medical Research University of Colorado-Denver Office of Grants and Contracts F-42 Denver CO 802910238 846049811 501c3 433111 Medical Research University of Florida Board of Trustees PO Box 113001 Gainesville FL 32611 596002052 501c3 381227 Medical Research University of Maryland Baltimore Sponsored Projects Acctng 220 Arch Baltimore MD 212011508 526002033 Maryland 23726 Medical Research University of Massachusetts Worcester 55 Lake Avenue North Worcester MA 016550002 043167352 Massachusetts 40313 Medical Research University of Michigan Attnthe Regents of Box 223131 Pittsburgh PA 152512131 386006309 501c3 21886 Medical Research University of Michigan Regents of the Box 223131 SSC Accounts Receivable PIttsburgh PA 152512131 386006309 501c3 69859 Medical Research University of Nebraska Medical Center 985045 Nebraska Medical Center Omaha NE 681985045 470049123 501c3 92947 Medical Research University of North Carolina 720 Martin Luther King Jr Blvd CB16 Chapel HIll NC 27599 566001393 501c3 615371 Medical Research University of North Carolina at Chapel Hill 104 Airport Drive Suite 2200 CB1350 Chapel HIll NC 27599 566001393 501c3 87086 Medical Research University of Pennsylvania PO Box 785541 Philadelphia PA 171785541 231352685 501c3 190055 Medical Research University of Pittsburgh Division of Endocrinology E1140 Bio Pittsburgh PA 15213 250965591 501c3 96739 Medical Research University Of South Florida PO Box 864568 Orlando FL 328864568 593102112 Florida 12747 Medical Research University of Texas Southwestern Medical Center Lock Box 845477 Dallas TX 752845477 756002868 Texas 21262 Medical Research University of Utah Utah Diabetes Center 615 Arapeen D Salt Lake City UT 84108 876000525 501c3 28052 Medical Research University of WA Grants 12455 Collections Drive Chicago IL 606930001 916001537 Washington 270724 Medical Research University of Wisconsin Madison Board of Regents 21 N Park St Ste 6401 Madison WI 53792 396006492 501c3 128078 Medical Research Vanderbilt University Department of Finance Dept AT 40303 Atlanta GA 311920303 620476822 501c3 10876 Medical Research Wake Forest University Health Sciences Medical Center Boulevard WinstonSalem NC 27157 223849199 501c3 23588 Medical Research Washington University in St Louis 700 Rosedale Avenue Campus Box 1034 St Louis MO 63012 460653611 501c3 11890 Medical Research Winthrop University Hospital Dept of Finance 700 Hicksville Road Bethpage NY 11714 111633486 501c3 15694 Medical Research Yale University Grant and Contract Financial Admini New Haven CT 065081873 080648973 501c3 208218 Medical Research 69 5 Part I Line 2 Subrecipient Monitoring Policy-medical research subawards-BRI has formal policies and procedures to assure full compliance with applicable policies and laws governing Federal Grants. The Subrecipient Monitoring Policy provides assurance that subrecipients comply with Federal Grant regulations. This policy sets the criteria to establish eligibility of subrecipients to provide annual audited financial reports and the annual OMB single audit report that identify compliance with federal laws and regulations. The reports are analyzed with emphasis on auditors assessment of subrecipient internal controls and a standardized Risk Assessment is presented to management on each subrecipient. A Management Letter is issued to each subrecipient showing any findings on their OMB single audit report, and measurements are set for increased monitoring when an elevated level of risk is established. Management has communicated with an educated administrative staff regarding implementation of this policy. The Director of Grants and Contracts is responsible for monitoring subrecipient adherence to financial regulations. The principal investigator is responsible for overseeing the satisfactory performance of the sub-award to ensure that goals are achieved. Unusual or unforeseen items will be investigated. X true true false true false false false false false false false Carla Greenbaum MD Director 212388 24000 6886 243274 Gerald Nepom MD PhD Ex Officio, Director 389687 89396 42000 2592 523675 Joyce Lammert MD PhD Director 443634 112527 19528 74702 9427 659818 John Corman MD Director 505321 175 18550 18054 21300 563400 Gary Kaplan MD Director 1040152 403531 19660 1081178 42468 2586989 Homer Lane Jr Executive Director, Chief Financial Officer 249016 58388 24000 8594 339998 Jane Buckner MD Research Member 259514 24000 2892 286406 William Kwok PhD Research Member 216089 742 24000 2892 243723 Lynn Rose Director Scientific Administration 181479 542 18528 4992 205541 Steven Ziegler PhD Research Member 188567 542 14392 4104 207605 James Lord MD Research Member 202127 17634 3804 223565 Part I Line 3 Benaroya Research Institute at Virginia Mason relies upon Virginia Mason Medical Centers a related organization Board Compensation and Benefits committee, a committee composed of independent board members to whom the Board has delegated the authority to approve all compensation and benefits for the executive leaders of the Medical Center. To ensure that such benefit plans are market competitive and reasonable, the Committee receives support and advice, including appropriate market comparability data, from an independent compensation consultant with expertise in the health care industry and access to relevant market data. See Schedule O for additional disclosure. Part I Line 4b The Medical Center has a Supplemental Executive Retirement Plan SERP. The SERP is a 457f nonqualified deferred compensation plan pursuant to which plan benefits are subject to a substantial risk of forfeiture, entered into when certain senior executives join the Medical Center. The plan was approved by the Boards Compensation and Benefits Committee, a committee composed of independent board members to whom the board delegates the authority to approve compensation and benefits for the Medical Centers most senior executives. The Committee receives advice from an independent compensation consultant to ensure that compensation and benefits, including the SERP, are market competitive and reasonable. A WA Econ Devel Fin Auth-2012 Series B 911493002 2012-06-01 10390000 See Part VI false true false A 965000 10390348 2550348 7840000 2013 true false true true A false true false true true 0.01690 0.01690 false false true A false true false false false false true A true Part I Line A Column F Purposes to currently refund WEDFA Series 2006C bonds issued 11/15/2006, and to fund research facility improvements. Part II Line 3 Difference between Part I, column e and Part II, Line 3 is investment earnings. X Advertising 1 85000 Donor Valuation false false false Part I Line 25 BRI received donated billboard space for BRI ads Form 990, Part III, Line 1 Benaroya Research Institute at Virginia Mason BRI is a world-renowned medical research institute whose work has resulted in major advances against autoimmune and immune-mediated diseases. BRI is affiliated with the Virginia Mason Health System, that provides governance oversight and development support by its division the Virginia Mason Foundation. In 2015, BRI researchers generated 78 scientific publications that were published in prestigious research journals and delivered 75 presentations at domestic and international research conferences. One in 20 Americans suffers from one or more autoimmune diseases, such as type 1 diabetes, multiple sclerosis, Crohns disease and rheumatoid arthritis to name a few, and more than one out of every four Americans suffer from diseases of the immune system, such as allergies and asthma. Because these diseases are connected in the way the immune system attacks the body, BRI scientists arent focused on eliminating one or two immune system diseases - they are taking on many more. As a world leader in scientific innovation, BRIs discoveries are having significant impact on people living with these diseases today - by improving the ability to predict disease risk, decreasing disease progression and making therapies safer and better. Form 990, Part III, Line 4 One of the unique qualities of BRI is the close integration of three types of medical research - laboratory research, translational research and clinical research - to improve peoples lives. Our scientists can address both the basic science issues and clinical applications, which is the best way to design studies with the highest potential for success. For BRI, discovery starts in the laboratory. 2015 advancements in translational research, immunology, clinical research and other areas are highlighted below. Form 990, Part III, Line 4a Funding for the Immune Tolerance Network ITN was awarded to BRIs Dr. Jerry Nepom in 2014 from the National Institute of Allergy and Infectious Disease NIAID of the National Institutes of Health NIH. The 7-year award, totaling 27 million annually supports the ITN, a research consortium established in 1999 with a primary focus on the development of new tolerogenic approaches for the treatment and prevention of disease in three clinical areas asthma and allergic diseases autoimmune diseases and immune-mediated rejection of transplanted solid organs, tissues and cells. As the Prime recipient of this grant BRI is responsible for the management of the overall grant from NIAID including oversight of all aspects of the Networks infrastructure. The major activities in 2015 were diverse, but centered on preserving the ITNs cohesive project focused environment and its framework which has proven so successful in the management of a large cooperative agreement grant. Key outcomes in 2015 include the following 1 Cross Network Integration A top priority in this reporting period was to continue the successful ITN infrastructure which is spread across three main operational sites. This required careful planning and collaboration as the ITNs major centers of operations are geographically diverse, located in Seattle, San Francisco and Bethesda. Very few changes were made to the existing network integration as the current model continues to successfully support the overall ITN program. Establishing new relationships and vital connections within the research community continued to be an ITN goal. 2 Operations and Clinical Trial Support The ITN program team at BRI issued 168 subawards in 2015 in support of 24 active ITN clinical trials and numerous supporting ITN mechanistic trials. 3 Supplemental Funding / Partnerships ITN central administration continued to focus on identifying additional opportunities for supplemental funding and/or funding partnerships. a Supplemental Funding Opportunities The ITN Program Team at BRI submitted three supplemental funding requests in 2015. All three were awarded bringing in additional funding to the ITN BRI. b Partnerships The ITN continued its relationship with pharmaceutical partners for partial funding for two ITN studies with NIAID as the clinical sponsor. 4 Publication Activity In 2015, 38 ITN publications were published in prestigious research journals and were presented at domestic and international research conferences. These publications represented ITN research in all therapeutic focus areas of the ITN Type 1 Diabetes, Transplant, Autoimmune disease and Allergy and Asthma. Form 990, Part III, Line 4b Translational research is a scientific approach that moves findings from the bench to the bedside and back in an expedient and systematic way. It translates new laboratory discoveries quickly into medical practices. Clinician findings are in turn shared with laboratory scientists to bring medical research full circle. This transfer of knowledge between laboratory scientists and physicians leads to improved patient care, health and well-being. The research emphasis of the BRI Translational Research Program is the area of immune-mediated disease. BRI scientists and collaborators work together to study blood and serum samples along with medical and demographic data collected from people with autoimmune and immune-mediated diseases. These include multiple sclerosis, type 1 diabetes, lupus, rheumatoid arthritis, inflammatory bowel disease, allergy and asthma. BRI maintains an extensive biorepository with samples dating back to 2000, including 7 disease categories and a biorepository of healthy people for comparison purposes. Advancements in 2015 include the following 1 New Biorepository Data Management system - The research technology team at BRI finalized a two-year project to make BRIs data infrastructure more modern, powerful, and flexible. The new system dramatically improves how BRI researchers find, use and analyze information. The team imported data on approximately 9,000 participants and 25,000 samples. All samples and health information used by scientists are de-identified and coded with a number. 2 Connecting Cancer to Immunotherapy Research - In addition to autoimmune disease research, BRI scientists are making advances in other diseases of the immune system. Clinical immunotherapies for cancer treatment are actively being investigated, as well as basic research focused on understanding how aspects of the immune system might be harnessed to fight cancer. In a new collaboration, BRI has partnered with Virginia Mason and Bristol Meyers Squibb in an agreement to develop a new tumor biorepository. It will include tissue, blood samples and demographic data from Virginia Mason cancer patients and will initially focus on archiving biosamples from pancreatic, colorectal, lung and breast tumors. 3 Translational Research Symposium -- the first annual Clinical and Translational Research Symposium, sponsored by the Wilske Center for Translational Research, took place at Virginia Mason Medical Center. The event connected researchers and clinicians by highlighting the range of clinical and translational research being conducted at Virginia Mason and BRI. Of the more than 100 research abstracts submitted, the Wilske committee selected the top eight abstracts for oral presentations. 4 Food Allergy Research -- Funding was received from Food Allergy Research Education FARE to identify and isolate the T cells that cause peanut allergy. The genes used by these T cells will be studied to understand why these cells are causing allergies. This information will then be used to discover how to effectively neutralize these cells and cure peanut allergy. 5 New Translational Research Scientist - Marc Gavin, PhD, joined BRIs Translational Research Program. Dr. Gavins laboratory is focused on understanding how therapeutic manipulation of the balance between regulatory and effector T cells alters immune responses in setting of pathogenic inflammation, chronic infection, and cancer. His group is also investigating how variation in the availability and usage of interleukin-2 impacts the regulatory/effector T cell balance in human autoimmune disease. Form 990, Part III, Line 4c BRI is dedicated to seeking ways to eliminate type 1 diabetes, while at the same time looking for therapies to prevent, reverse and intervene in the disease at all stages. BRI is an international leader in type 1 diabetes research and has investigated it for more than 30 years, starting with identification of a genetic marker for the disease. Progress in 2015 includes 1 Leadership of Diabetes Network -- BRI became the leader of Type 1 Diabetes TrialNet, a National Institutes of Health-funded clinical trial network for type 1 diabetes prevention and early treatment. Carla Greenbaum, MD, director of BRIs Diabetes Research Program, was named chair of TrialNet. BRI also became the TrialNet Hub. The hub includes 21 clinical centers working in cooperation with more than 200 screening and clinical research sites through the United States and seven other countries. 2 EXTEND Study -- A new Immune Tolerance Network ITN type 1 diabetes trial was launched. The principal investigators are BRI scientists Carla Greenbaum, MD, and Jane Buckner, MD. The EXTEND trial Preserving Beta-Cell Function with Tocilizumab in New Onset Type 1 Diabetes will test whether tocilizumab ACTEMRA Genentech, an antibody that targets the interleukin-6 IL-6 receptor, can slow disease progression and help maintain natural insulin production in adults with new-onset type 1 diabetes. There are presently no treatments that can permanently halt or reverse the autoimmune-mediated destruction of insulin-producing beta cells in patients with type 1 diabetes. Form 990, Part III, Line 4d 1 Clinical Research Program Benaroya Research Institute oversees all clinical research at Virginia Mason Medical Center and BRI, ensuring consistent application of the federal regulations governing human subject research. The Clinical Research Program CRP includes the BRI Institutional Review Board IRB, which reviews and approves all investigator-initiated clinical research conducted at BRI and the Virginia Mason Medical Center VMMC. The CRP Administrative group CRPA contributes to and maintains a clinical quality assurance program designed to ensure regulatory and financial compliance to applicable regulations and internal policies. The CRPA also maintains a cadre of highly trained clinical research staff who work closely with individual investigators at VMMC. This partnership ensures a consistent and compliant approach to the implementation of clinical studies at VMMC. Active studies span a wide variety of diseases and conditions, including cardiology, neurology, anesthesiology, and cancer. In 2015, CRPA staff enrolled over 5,000 participants into 440 open studies. Approximately 170 research investigators are conducting human subject research at VMMC. The IRB was responsible for the initial or continuing review of over 500 studies. 2 Immunology Research Program a Technology Pipeline --BRI is conducting new research to discover and interrogate the rare cells that cause autoimmune diseases to improve diagnosis and therapy. The Institute is using several of its unique and pioneering technologies together to create a technology pipeline approach to find and study these rare cells. Scientists finding key molecular patterns of the cells in individuals who have immune-mediated diseases and those patterns that determine who responds to treatment. b The Kwok laboratory extended studies of allergic T lymphocytes using tetramer technologies to include description of cells associated with walnut and cat allergies. c Dr. Bettellis laboratory used a model of multiple sclerosis to change the movement of immune cells into the central nervous system, identifying keytrafficking molecules that influence disease progression. d Dr. Peter Linsley, leading BRIs systems immunology group, characterized transcriptional profiles that distinguished immune response patterns for a dozen different tumor types, identifying tumor-specific checkpoints that correlate with the patients prognosis. 3 Matrix Biology Research Program Collaborative studies between investigators in BRIs matrix biology and immunology programs used an oral inhibitor to successfully interrupt deposition of tissue matrix molecules for prevention of autoimmune diabetes in a model system. Form 990, Part VI, Section A, Line 1a The governing body delegates to an Executive Committee comprised of four officers of the Board and the Chairs of each standing Board Committee, the authority of the Board of Directors in the management of the corporation as may be deemed by the Executive Committee to be appropriate, to be exercised in time periods between regularly scheduled meetings of the Board of Directors provided that the Executive Committee has the authority to act only in time sensitive or emergency situations. The Director and the Executive Director of the corporation serve as ex officio members of the Executive Committee without voting rights. The Executive Committee does not have the authority to amend, alter or repeal the bylaws elect, appoint or remove any member of such Executive Committee or any director or officer of the corporation amend the articles of incorporation adopt a plan of merger or adopt a plan of consolidation with another corporation authorize the sale, lease or exchange of all or substantially all the property and assets of the corporation not in the ordinary course of business authorize the voluntary dissolution of the corporation or revoke proceedings therefore adopt a plan for the distribution of the assets of the corporation or amend, alter or repeal any resolution of the Board which by its terms provides that it shall not be amended, altered or repealed by such Executive Committee. The Executive Committee also serves as the planning committee for the Board of Directors and oversees any compliance issues raised by the Board of Directors. Form 990, Part VI, Section A, Line 6, 7 Virginia Mason Health System VMHS is the sole corporate member of Benaroya Research Institute at Virginia Mason BRI. VMHS as the sole voting member has the following approval rights a election or appointment of Directors and Officers of the Board of Directors b removal of Directors and Officers of the Board of Directors including any executive officer of the corporation c approval of all long-range and short-range plans proposed by the Board of Directors d approval of the annual capital and operating budgets proposed by the Board of Directors e approval of the borrowing of funds where the amount borrowed is in excess of Five Hundred Thousand Dollars 500,000 f approval of the sale, lease, exchange, mortgage, pledge or disposal of all or substantially all of the property and assets g approval of all amendments to or repeal of the Agreement Association or the Bylaws of the corporation h all other rights and powers as specified in the Washington Nonprofit Corporation Act. Form 990, Part VI, Section B, Line 11b The Virginia Mason Health System Audit and Compliance Committee ACC, a committee composed of independent community members has been delegated responsibility for oversight of the annual Form 990 preparation process including a selection, engagement, and review of the performance of the independent tax preparer b review of the annual draft Form 990 tax return, and c recommendation of the final Form 990 tax return for review to the BRI Board of Directors. Annually, at the September meeting, management and the tax preparer provides the ACC with an initial draft of the Form 990 and present an overview of the Form 990 preparation process. The final draft Form 990 is reviewed and approved by the ACC in November followed by a Board review of the final Form 990 prior to filing. The final Form 990 tax return is provided to each member of the Board of Directors via electronic delivery. Form 990, Part VI, Section B, Line 12c The Virginia Mason Health System Governance Committee has been delegated accountability for oversight of the process for disclosure, evaluation and management of conflict of interest involving any member of the Benaroya Research Institute at Virginia Mason BRI Board of Directors, executive leadership or key employees Covered Person. Pursuant to the Conflict of Interest Policy, an annual conflict of interest questionnaire is distributed to all Covered Persons. In addition, a Covered Person has an on-going duty to disclose the existence of a conflict of interest at any time an actual or potential conflict arises. Each Covered Person is required upon appointment and annually thereafter to attest to a statement that affirms that such person has a received a copy of the Conflict of Interest Policy b has read and understands the Policy c has agreed to comply with the Policy and d understands that BRI is a charitable organization and that in order to maintain its federal tax exemption must engage in activities that accomplish its tax-exempt purposes. Written disclosures are reviewed by the Governance Committee to determine if an actual or potential conflict of interest exists and if so, how it should be managed. The Covered Person is informed in writing regarding the determination the Conflict of Interest Management Plan. No Covered Person with an actual or potential conflict of interest shall engage in an activity on BRIs behalf related to the disclosed actual or potential Conflict of Interest unless such activity is permitted by the Conflict of Interest Management Plan or until the Covered Person has undertaken all steps set forth in the Management Plan to manage, reduce or eliminate the conflict. All Covered Persons have a duty to disclose the existence of any actual or potential conflict of interest with respect to meeting agenda items. The Conflict of Interest Policy requires that copies of the Conflict of Interest Questionnaire be completed annually by each covered Person and any Conflict of Interest Management Plan be maintained. Form 990, Part VI, Section B, Line 15 The VMHS Compensation and Benefits Board Committee, a committee composed solely of independent directors none of whom have a conflict of interest, is accountable for setting reasonable total compensation packages for each executive, officer and key employee Executive consistent with BRIs compensation philosophy and principles. The Committee approves annual goals and performance criteria which are used in determining merit increases and variable compensation opportunities. The Committee assesses performance against these goals. The Committee selects and engages a qualified independent compensation consultant to review and analyze the total compensation and benefits packages of the Executives. The Committee as part of its analysis obtains from the compensation consultant appropriate comparability data including total compensation paid by similarly situated organizations for positions that are functionally comparable to each of the Executives. The Committee will consider the significant terms of the agreement with each Executive including the total compensation to be paid and the employees duties and responsibilities. Consistent with the compensation philosophy and principles, the Committee approves total compensation packages for each of the Executives based on information presented to the Committee, reasonableness and the best interest of BRI. The Committees decisions regarding compensation for each Executive are documented in written resolutions and minutes of the Committee. The Committee promptly reports its actions to the VMHS board which reports are reflected in the Boards minutes. The individual positions who were reviewed in 2015 were the Board Director, Carla Greenbaum, BRI Director, and Executive Director and Chief Financial Officer. Form 990, Part VI, Section C, Line 19 The organizations Articles, Bylaws, Conflict of Interest Policy and financial statements are made available upon request. Virginia Mason Health System (VMHS) 1100 Ninth Ave Seattle WA 98101 911351110 Fundraising WA Sec 501c3 7 N/A true Virginia Mason Medical Center 1100 Ninth Ave Seattle WA 98101 910565539 Health Care WA Sec 501c3 3 VMHS false Virginia Mason Institute 1100 Ninth Ave Seattle WA 98101 263763656 Education/Research WA Sec 501c3 9 VMMC false false false true false false false false false false true true false false true false true true false false Benaroya Research Institute at Virginia Mason 1201 Ninth Avenue Seattle WA 98101 910653422 0 0 0 67482221 67482221 60624 15156 0 0 0 Virginia Mason Medical Center 1100 Ninth Avenue Seattle WA 98101 910565539 X 108173 46593 154766 1024957778 1025112544 920931 230233 0 0 0 Virginia Mason Health System 1100 Ninth Avenue Seattle WA 98101 911351110 0 0 0 14005171 14005171 12582 3146 0 0 0 Virginia Mason Institute 1100 Ninth Avenue Seattle WA 98101 263763656 0 0 0 6526468 6526468 5863 1466 0 0 0